US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 21:07:32 Source:worldViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Harris accepts debate invite to face off with Trump's VP pick, which may come at convention
Next:Medics remove 150 MAGGOTS from a woman's mouth after dental procedure left her with rotting tissue
You may also like
- Cruise worker 'murders newborn son on board ship': Shocked co
- A Michigan man and his dog are rescued from an inland lake's icy waters
- Senior CPC official stresses protection, inheritance of cultural heritage
- Top legislature to review bills on patriotic education, safeguarding national secrets
- Sweden beats France, Britain relegated after losing to Norway at hockey worlds
- Female lawmakers, political advisors shine at China's ongoing two sessions
- Anne Hathaway addresses claims Harry Styles inspired her age
- Chinese premier presides over meeting of Central Financial Commission
- What's next for Iran after death of its president in crash?